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Thompson D, McGarry L
Innovus Research, Inc, Medford, MA, USA
OBJECTIVE: Prophylactic administration of low-
molecular weight heparin (LMWH) has been shown to
reduce the occurrence of venous thromboembolism 
(VTE) among acutely-ill medical patients in the clinical
trial setting. The purpose of this study was to examine
outcomes and costs of LMWH thromboprophylaxis
among medical inpatients in real-world clinical practice.
METHODS: Using a large, geographically-diverse, multi-
hospital U.S. database, we identiﬁed persons aged ≥40
years who were hospitalized for ≥6 days with an acute
medical condition (including circulatory disorders, respi-
ratory disorders, infectious diseases, or neoplasms) during
calendar year 2000. From these patients we identiﬁed
those who received either thromboprophylaxis with the
LMWH enoxaparin or no thromboprophylaxis. Surgical
patients, patients with conditions requiring anticoagulant
therapy, and those medically ineligible for anticoagula-
tion were excluded. We compared the incidence of VTE
(deﬁned as deep-vein thrombosis [DVT] or pulmonary
embolism [PE]) and death during the hospital stay, as well
as length of inpatient stay and total costs, in the two
cohorts. RESULTS: We identiﬁed 215 patients receiving
enoxaparin prophylaxis and 3595 receiving no prophy-
laxis. The risk of VTE over the course of the hospitaliza-
tion was 58% lower with enoxaparin prophylaxis than
with no prophylaxis (3.3% versus 7.9%; p < 0.001); there
was no difference in the risk of death (7.4% versus 7.3%;
p = 0.96). Length of stay in hospital and costs of inpa-
tient stay were nominally higher in the group receiving
enoxaparin prophylaxis versus no prophylaxis (10.4 days
versus 10.1 days; US$10,497 versus US$9,904), although
the magnitude of these differences was not signiﬁcant 
(p = 0.40 for length of stay; p = 0.29 for costs). CON-
CLUSIONS: Prophylaxis with LMWH was found to be
effective in reducing the risk of thromboembolism in
medical inpatients in real-world clinical practice;
however, no corresponding reductions in length of hos-
pital stay and inpatient costs were observed.
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OBJECTIVES: To estimate the avoidable health care
costs of uncontrolled hypertension in Canada.
METHODS: We used an established cost of illness model
to estimate cost of cardiovascular (CV) hospitalisations
at current prevalence of hypertension to the Canadian
health care system, and the level of these costs if hyper-
tension was successfully treated to target levels. Two 
populations were examined: hypertensives in the general
population; and a subpopulation with both hypertension
and Non-Insulin Dependent Diabetes Mellitus (NIDDM).
Population data were sourced from the 2001 census.
Prevalence of hypertension in the general population 
was taken from the Canadian Heart Health Survey and
in NIDDM was calculated from Diabetes in Canada 
and Canadian Diabetes Association data. The HOT trial
and Framingham Risk Proﬁle equation were used to
examine the relationship between achieved blood pres-
sure and 3 major CV events—stroke, congestive heart
failure (CHF), and symptomatic acute myocardial infarc-
tion (AMI). Cost of CV events were taken from the
Ontario Case Costing Project (AMI and CHF) and the
Canadian Economic Burden of Illness Study (stroke). Sto-
chastic simulation was used to construct conﬁdence inter-
vals. RESULTS: The model estimated that 5.3 million 
Canadians over age 18 have hypertension. Uncontrolled
hypertension was associated with 17,000 excess CV
events and costs of C$306 million (95%CI: C$154–
632m) annually. Among 309,000 hypertensives with
NIDDM, uncontrolled hypertension was associated with
4,000 excess CV events annually and costs of C$68
million (95%CI: C$37–103m). CONCLUSIONS:
Uncontrolled hypertension contributes substantially to
the overall cost of cardiovascular disease in Canada. Dia-
betic hypertensives represented 22% of the avoidable cost
of hypertension and 6% of the hypertensives population.
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OBJECTIVES: Deep venous thrombosis (DVT) is a
common cardiovascular condition occurring in 2 per
1000 persons/year. Despite its frequency, the economic
impact of DVT has not been quantiﬁed. During a
prospective Canadian multicenter study of longterm out-
comes after DVT, we quantiﬁed DVT-related resource 
utilization during the four months following diagnosis.
METHODS: The study population consisted of 153
patients diagnosed with acute DVT at 1 of 7 participat-
ing hospitals. Data on DVT-related hospitalisations,
physician visits, diagnostic tests, medical devices, para-
medical services and indirect costs were collected for 
the 4-month period following diagnosis. Data sources
included weekly patient-completed diaries, nurse-
completed case report forms (baseline, 1, 4 months, and
